Statin vs placebo, serious vascular events

STATIN (SIMVASTATIN 40MG DAILY, ATORVASTATIN 80MG DAILY, PRAVASTATIN 40MG DAILY) VS. PLACEBO, SERIOUS VASCULAR EVENTS

Study population:

Secondary prevention of CVD.

Patients had a history of ischaemic or haemorrhagic  stroke or TIA.

Comments:

Serious vascular events (non-fatal stroke, non-fatal myocardial infarction, vascular death) and all-cause mortality including sudden deaths